QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DMRA

QT68Damora Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
21.23
-0.19-0.89%
OverviewShort InterestFilings
DMRAQT68Damora Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
21.23-0.89%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own3.15%
Shs Outstand61.55M
Perf Week-0.61%
Market Cap1.32BForward P/E-EPS next Y-2.11Insider Trans0.00%Shs Float-Perf Month-11.69%
Enterprise Value786.91MPEG0.00EPS next Q-Inst Own-Short Float-Perf Quarter10.57%
Income-10904401297.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-29.23%
Sales-P/B0.06EPS next Y-7.92%ROA-43.91%Short Interest-Perf YTD-7.74%
Book/sh8.29P/C-EPS next 5Y-ROE-122.61%52W High38.33 -44.61%Perf Year559.32%
Cash/sh8.66P/FCF-EPS past 3/5Y-ROIC-46.73%52W Low2.45 766.53%Perf 3Y-
Dividend Est.-EV/EBITDA-3.35Sales past 3/5Y-Gross Margin0.00%Volatility5.15% 5.67%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)1.84Perf 10Y-
Dividend Ex-Date-Quick Ratio22.48Sales Y/Y TTM-Profit Margin0.00%RSI (14)41.51Recom2.00
Dividend Gr. 3/5Y-Current Ratio22.48EPS Q/Q-SMA20-6.04%Beta2.16Target Price40.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-12.24%Rel Volume4.75Prev Close21.42
Employees7LT Debt/Eq0.07Earnings-SMA2004.07%Avg Volume367.65KPrice21.23
IPO DateMar 10, 2026Option/ShortNo / YesEPS/Sales Surpr.-Net Debt/EBITDA2.26Volume1,747,141Change-0.89%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-11-26InitiatedH.CBuy$45
May-28-26InitiatedWedbushOutperform$35
Apr-23-26InitiatedRBC CapitalOutperform$40
Latest News
Jun-12-26
Jun-12-2610:07AM
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price TargetBenzinga
Jun-11-26
Jun-11-2607:55AM
HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A001
Gross Profit00-1
Selling, General and Administrative Excl. Other101012
Research and Development201624
Other Operating Expense010
Operating Income-211-17-36
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-152
Net Income Before Taxes-210-21-38
Income Taxes
000
Consolidated Net Income-210-21-38
Net Income From Continuing Operations-210-21-38
Net Income-210-21-38
EPS (Recurring)-158.13-18.53-36.08
EPS (Basic, Before Extraordinaries)-158.13-18.53-36.08
EPS (Diluted)-158.13-18.53-36.08
EBITDA-210-21-38
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding111
Market Capitalization23——
Operating Lease Expense
———
Insider Trading Volume
$24.04$22.02$20.01$18.00$15.98● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR